Abstract:Membranous nephropathy (MN) is a rare auto-immune disease where the glomerulus is targeted by circulating auto-antibodies mostly against podocyte antigens, which results in the formation of electron-dense immune complexes, activation of complement and massive proteinuria. MN is the most common cause of nephrotic syndrome in adults leading to severe thrombotic complications and kidney failure. This review is focused on the recent therapeutic and pathophysiological advances that occurred in the last two years. For a long time, we were lacking a head-to-head comparison between cyclophosphamide considered as the gold standard therapy and other medications, notably rituximab. Substantial progress has been achieved owing to three randomized controlled trials. MENTOR (Membranous Nephropathy Trial of Rituximab) and STARMEN (Sequential Therapy with Tacrolimus and Rituximab in Primary Membranous Nephropathy) conclusively established that calcineurin inhibitor-based regimens are slower to result in an immunologic response than rituximab or cyclophosphamide, achieve fewer complete clinical remissions, and are less likely to maintainremission. Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (RI-CYCLO) suggested that competition between cyclophosphamide and rituximab remains open. Given the technological leap combining laser microdissection of glomeruli and mass spectrometry of solubilized digested proteins, four “new antigens” were discovered including NELL-1 and Semaphorin 3B in so-called primary MN, and exostosins 1 and 2 and NCAM 1 in lupus MN. NELL-1 is associated with about 8% of primary MN and is characterized by segmental immune deposits and frequent association with cancer (30%). Semaphorin 3B-associated MN usually occurs in children, often below the age of two years, where it is the main antigen, representing about 16% of non-lupus MN in childhood. Exostosins 1/2 and NCAM 1 are associated with 30% and 6% of lupus MN, respectively. Exostosins 1/2 (EXT1/2) staining is associated with a low rate of end-stage kidney disease (ESKD) even in mixed classes III/IV+V. These findings already lead to revisiting the diagnostic and therapeutic algorithms toward more personalized medicine.

From Diagnosis to Dialysis: Managing Primary Membranous Nephropathy in a Patient Living With Human Immunodeficiency Virus (HIV)

Membranous Nephropathy: Pathogenesis and Treatments

Membranous nephropathy associated with viral infection

Anti-phospholipase A2 receptor-associated membranous nephropathy with human immunodeficiency virus infection treated with telitacicept: A case report

The changing landscape of HIV-associated kidney disease

Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

HIV-associated kidney disease: the changing spectrum and treatment priorities

Ten Tips on Immunosuppression in Primary Membranous Nephropathy

Advances in Membranous Nephropathy

Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy

Membranous nephropathy: Mechanistic insights and therapeutic perspectives

Recent Advances in Clinical Diagnosis and Pharmacotherapy Options of Membranous Nephropathy

Renal Pathology and clinical features of patients with human immunodeficiency virus infection complicated with kidney diseases

An Updated Review of Membranous Nephropathy

Immunosuppressive Therapy in Primary Membranous Nephropathy with Compromised Renal Function

A low rate of end-stage kidney disease in membranous nephropathy: A single centre study over 2 decades

Overlap of Primary Membranous Nephropathy, IgA Nephropathy, and Diabetic Nephropathy: A Case Report

Pneumocystis jirovecii Pneumonia and HIV-Associated Nephropathy in Acute HIV Infection

Uremic syndrome with newly diagnosed HIV infection: reflections on a particular case

Atherosclerosis and Cardiovascular Complications in People Living with HIV: A Focused Review

Cardiac and Renal Comorbidities in Aging People Living With HIV